Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study

被引：1

作者：

Puspitasari, Metalia ^{[1
]}

Sattwika, Prenali D. ^{[1
,2
,3
]}

Hidayat, Auliana R. P. ^{[1
]}

Wijaya, Wynne ^{[1
]}

Wardhani, Yulia ^{[1
]}

Intansari, Umi S. ^{[4
]}

Kertia, Nyoman ^{[1
]}

Purwanto, Bambang ^{[5
]}

Thobari, Jarir At ^{[2
,6
]}

机构：

[1] Univ Gadjah Mada, Dr Sardjito Gen Hosp, Fac Med Publ Hlth & Nursing, Dept Internal Med, Yogyakarta, Indonesia

[2] Univ Gadjah Mada, Dr Sardjito Gen Hosp, Fac Med, Clin Epidemiol & Biostat Unit, Yogyakarta, Indonesia

[3] Univ Oxford, Radcliffe Dept Med, Div Cardiovasc Med, Cardiovasc Clin Res Facil, Oxford, England

[4] Univ Gadjah Mada, Dr Sardjito Gen Hosp, Fac Med Publ Hlth & Nursing, Dept Clin Pathol & Lab Med, Yogyakarta, Indonesia

[5] Univ Sebelas Maret, Fac Med, Dept Internal Med, Surakarta, Indonesia

[6] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Pharmacol & Therapy, Yogyakarta, Indonesia

来源：

BMC NEPHROLOGY | 2023年 / 24卷 / 01期

关键词：

COVID-19; vaccines; Booster; End-stage renal disease; Haemodialysis; Immunogenicity; Safety; HUMORAL RESPONSE;

D O I：

10.1186/s12882-023-03218-x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundA significant decrease in antibody titres several months after COVID-19 primary vaccination in end-stage kidney disease (ESKD) patients receiving maintenance haemodialysis has recently been reported. The waning in antibody titres has led to the recommendations for a booster dose to increase the antibody titres after vaccination. Consequently, it is crucial to analyse the long-term humoral immune responses after COVID-19 primary vaccination and assess the immunogenicity and safety of booster doses in haemodialysis (HD) patients.MethodsPatients on maintenance haemodialysis who received the primary vaccine of CoronaVac (Sinovac) vaccine were administered with BNT162b2 (Pfizer-BioNTech) as the booster dose. The immunogenicity was assessed before (V1), one month (V2) and eight months (V3) after the primary vaccination, as well as one month after the booster dose (V4). Patients were followed up one month after the booster dose to assess the adverse events (AEs).ResultsThe geometric mean titre (GMT) of anti-SARS-CoV-2 S-RBD IgG antibody at 8 months after the primary vaccination increased significantly to 5,296.63 (95%CI: 2,930.89-9,571.94) U/mL (p = < 0.0001) compared to before the primary vaccination. The GMT also increased significantly to 19,142.56 (95% CI: 13,489.63-27,227.01) U/mL (p < 0.0001) 1 month after the booster vaccine. Meanwhile, the median inhibition rate of neutralizing antibodies (NAbs) at 8 months after the primary vaccine and 1 month after the booster dose were not significantly different (p > 0.9999). The most common AEs after the booster dose included mild pain at the injection site (55.26%), mild fatigue (10.53%), and swelling at the injection site (10.53%). No serious AEs were reported.ConclusionsThe majority of ESKD patients on haemodialysis mounted a good antibody response to the BNT162b2 booster vaccination with tolerable adverse events.

引用

页数：14

共 32 条

[1] Humoral Response to the Third Dose of BNT162b2 COVID-19 Vaccine among Hemodialysis Patients [J].

Agur, Timna ;

Zingerman, Boris ;

Ben-Dor, Naomi ;

Alkeesh, Weaam ;

Steinmetz, Tali ;

Rachamimov, Ruth ;

Korzets, Asher ;

Rozen-Zvi, Benaya ;

Herman-Edelstein, Michal .

NEPHRON, 2023, 147 (3-4) :185-192

[2] Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial [J].

Al Kaabi, Nawal ;

Zhang, Yuntao ;

Xia, Shengli ;

Yang, Yunkai ;

Al Qahtani, Manaf M. ;

Abdulrazzaq, Najiba ;

Al Nusair, Majed ;

Hassany, Mohamed ;

Jawad, Jaleela S. ;

Abdalla, Jehad ;

Hussein, Salah Eldin ;

Al Mazrouei, Shamma K. ;

Al Karam, Maysoon ;

Li, Xinguo ;

Yang, Xuqin ;

Wang, Wei ;

Lai, Bonan ;

Chen, Wei ;

Huang, Shihe ;

Wang, Qian ;

Yang, Tian ;

Liu, Yang ;

Ma, Rui ;

Hussain, Zaidoon M. ;

Khan, Tehmina ;

Saifuddin Fasihuddin, Mohammed ;

You, Wangyang ;

Xie, Zhiqiang ;

Zhao, Yuxiu ;

Jiang, Zhiwei ;

Zhao, Guoqing ;

Zhang, Yanbo ;

Mahmoud, Sally ;

ElTantawy, Islam ;

Xiao, Peng ;

Koshy, Ashish ;

Zaher, Walid Abbas ;

Wang, Hui ;

Duan, Kai ;

Pan, An ;

Yang, Xiaoming .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01) :35-45

[3] SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis [J].

Bensouna, Ilias ;

Caudwell, Valerie ;

Kubab, Sabah ;

Acquaviva, Sandra ;

Pardon, Agathe ;

Vittoz, Nathalie ;

Bozman, Dogan-Firat ;

Hanafi, Latifa ;

Faucon, Anne -Laure ;

Housset, Pierre .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (02) :185-+

[4] Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients [J].

Bruminhent, Jackrapong ;

Setthaudom, Chavachol ;

Kitpermkiat, Rungthiwa ;

Kiertiburanakul, Sasisopin ;

Malathum, Kumthorn ;

Assanatham, Montira ;

Nongnuch, Arkom ;

Phuphuakrat, Angsana ;

Chaumdee, Pongsathon ;

Janphram, Chitimaporn ;

Thotsiri, Sansanee ;

Chuengsaman, Piyatida ;

Boongird, Sarinya .

SCIENTIFIC REPORTS, 2022, 12 (01)

[5]

Cheng CY, 2022, J INFECTION, V84, pE98, DOI 10.1016/j.jinf.2022.04.011

[6] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study [J].

Costa Clemens, Sue Ann ;

Weckx, Lily ;

Clemens, Ralf ;

Almeida Mendes, Ana Verena ;

Souza, Alessandra Ramos ;

Silveira, Mariana B., V ;

Farias da Guarda, Suzete Nascimento ;

de Nobrega, Maristela Miyamoto ;

de Moraes Pinto, Maria Isabel ;

Gonzalez, Isabela G. S. ;

Salvador, Natalia ;

Franco, Marilia Miranda ;

de Avila Mendonca, Renata Navis ;

Queiroz Oliveira, Isabelle Silva ;

de Freitas Souza, Bruno Solano ;

Fraga, Mayara ;

Aley, Parvinder ;

Bibi, Sagida ;

Cantrell, Liberty ;

Dejnirattisai, Wanwisa ;

Liu, Xinxue ;

Mongkolsapaya, Juthathip ;

Supasa, Piyada ;

Screaton, Gavin R. ;

Lambe, Teresa ;

Voysey, Merryn ;

Pollard, Andrew J. .

LANCET, 2022, 399 (10324) :521-529

[7] Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients [J].

De Vriese, An S. ;

Van Praet, Jens ;

Reynders, Marijke ;

Heylen, Line ;

Viaene, Liesbeth ;

Caluwe, Rogier ;

Schoutteten, Melanie ;

De Bacquer, Dirk .

KIDNEY INTERNATIONAL REPORTS, 2022, 7 (07) :1103-1107

[8]

Duarte LF, 2021, FRONT IMMUNOL, P1

[9]

Food and Drug Administration, 2020, ROCH DIAGN EL ANTISA

[10]

Food and Drug Administration. Guidance for Industry, 2007, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials

← 1 2 3 4 →